{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:22Z","timestamp":1793146402836,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NIH","doi-asserted-by":"publisher","award":["R01-NS113425"],"award-info":[{"award-number":["R01-NS113425"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VA","award":["I01-CX000916"],"award-info":[{"award-number":["I01-CX000916"]}]},{"name":"NIH\/NCI training","award":["T32-CA070085"],"award-info":[{"award-number":["T32-CA070085"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant malignancies, driven in part by heterogeneous, therapy-resistant glioma stem cells (GSCs). Improving clinical outcomes will require innovative therapeutic approaches that target unique molecular vulnerabilities. The mitogen-activated protein kinase (MAPK) pathway drives tumor progression across multiple cancers, including GBM. MAPK-interacting kinases (MNK1\/2) represent MAPK downstream effectors that phosphorylate eukaryotic translation initiation factor 4E (eIF4E), a regulator of oncogenic and anti-apoptotic mRNA translation. We previously identified pharmacological MNK inhibition as a promising therapeutic strategy for GBM, but most available MNK inhibitors lack specificity. Methods: Novel MNK inhibitor compounds were developed using medicinal chemistry optimization and evaluated through molecular docking and kinome profiling analyses. Antineoplastic activity was assessed in established GBM cell lines and patient-derived glioma stem cell models cultured as 3-D neurospheres under stem cell-permissive conditions. Effects on MNK signaling, cell viability, neurosphere growth, migration, invasion, and apoptosis were analyzed using immunoblotting, flow cytometry, viability assays, wound healing assays, and 3-D invasion assays. In addition, a compound screen was performed to identify therapeutic agents that enhance MNK-targeted therapy, followed by validation using pharmacological inhibition and siRNA-mediated knockdown approaches. Results: Our next-generation MNK inhibitor NUCC-201893 exhibited high target specificity and greater potency than the lead compound NU808, effectively suppressing eIF4E phosphorylation, GBM cell viability, neurosphere growth, migration, and invasion. Compound screening identified DNA methyltransferase (DNMT) inhibition as a potent enhancer of MNK blockade. Pharmacological DNMT inhibition enhanced the cytotoxic effects of siRNA-mediated MNK1 knockdown, while concurrent pharmacological inhibition of MNKs and DNMT resulted in greater suppression of neurosphere growth and robust induction of apoptotic responses in GSCs. Conclusions: These findings identify dual MNK and DNMT inhibition as a promising combinatorial strategy that effectively triggers antineoplastic effects in GBM cells and GSCs.<\/jats:p>","DOI":"10.3390\/cancers18132086","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:16:44Z","timestamp":1782699404000},"page":"2086","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-0998","authenticated-orcid":false,"given":"Candice","family":"Mazewski","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5912-3505","authenticated-orcid":false,"given":"Ricardo E.","family":"Perez","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purav P.","family":"Vagadia","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Northwestern University, Evanston, IL 60208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Preventive Medicine-Biostatistics & Informatics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-5051","authenticated-orcid":false,"given":"Gary E.","family":"Schiltz","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Chemistry, Northwestern University, Evanston, IL 60208, USA"},{"name":"Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-850X","authenticated-orcid":false,"given":"Frank","family":"Eckerdt","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA"},{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA"},{"name":"Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018\u20132022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41571-025-01020-2","article-title":"Targeting the glioblastoma resection margin with locoregional nanotechnologies","volume":"22","author":"Kisby","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","first-page":"363","article-title":"Comprehensive understanding of glioblastoma molecular phenotypes: Classification, characteristics, and transition","volume":"21","author":"Xu","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-med-042420-102102","article-title":"New Approaches to Glioblastoma","volume":"73","author":"Khasraw","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/neuonc\/noaa259","article-title":"The evolution of the cancer stem cell state in glioblastoma\u2014Emerging insights into the next-generation of functional interactions","volume":"23","author":"Mitchell","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41568-022-00486-x","article-title":"Brain cancer stem cells: Resilience through adaptive plasticity and hierarchical heterogeneity","volume":"22","author":"Gimple","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1101\/gad.324301.119","article-title":"Glioblastoma stem cells: Lessons from the tumor hierarchy in a lethal cancer","volume":"33","author":"Gimple","year":"2019","journal-title":"Genes Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/CCO.0000000000000679","article-title":"Mechanisms of invasion in glioblastoma","volume":"32","author":"Chouleur","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Aitchison, E.E., Dimesa, A.M., and Shoari, A. (2025). Matrix Metalloproteinases in Glioma: Drivers of Invasion and Therapeutic Targets. BioTech, 14.","DOI":"10.3390\/biotech14020028"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1541-7786.MCR-16-0172","article-title":"MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma","volume":"14","author":"Bell","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1128\/MCB.24.15.6539-6549.2004","article-title":"Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development","volume":"24","author":"Ueda","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acs.jmedchem.1c00368","article-title":"Update on the Development of MNK Inhibitors as Therapeutic Agents","volume":"65","author":"Xu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-18-1602","article-title":"MNK1\/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ","volume":"79","author":"Guo","year":"2019","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/febs.13895","article-title":"Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion","volume":"283","author":"Bruno","year":"2016","journal-title":"FEBS J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1021\/acs.jmedchem.4c03158","article-title":"Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia","volume":"68","author":"Vagadia","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/cbdd.13585","article-title":"Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening","volume":"94","author":"Mishra","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1039\/D3MD00121K","article-title":"Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer","volume":"14","author":"Fernandez","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/fcp.12759","article-title":"Inhibition MNK-eIF4E-beta-catenin preferentially sensitizes gastric cancer to chemotherapy","volume":"36","author":"Yang","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12094-017-1724-0","article-title":"Inhibiting ERK\/Mnk\/eIF4E broadly sensitizes ovarian cancer response to chemotherapy","volume":"20","author":"Liu","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cellsig.2016.06.005","article-title":"Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy","volume":"28","author":"Grzmil","year":"2016","journal-title":"Cell. Signal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.canlet.2014.12.029","article-title":"Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells","volume":"357","author":"Teo","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1541-7786.MCR-17-0397","article-title":"Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation","volume":"16","author":"Bell","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1541-7786.MCR-18-1193","article-title":"Potent Antineoplastic Effects of Combined PI3Kalpha-MNK Inhibition in Medulloblastoma","volume":"17","author":"Eckerdt","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.febslet.2013.06.045","article-title":"Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a)","volume":"587","author":"Stead","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107652","DOI":"10.1016\/j.bioorg.2024.107652","article-title":"Targeting DNA methyltransferases for cancer therapy","volume":"151","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"118255","DOI":"10.1016\/j.ejmech.2025.118255","article-title":"DNMT1 drives glioma progression and modulates therapy response: A novel therapeutic target","volume":"301","author":"Armoundas","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1038\/s41598-020-78788-z","article-title":"Combined PI3Kalpha-mTOR Targeting of Glioma Stem Cells","volume":"10","author":"Eckerdt","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2144\/000114372","article-title":"A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids","volume":"60","author":"Eckerdt","year":"2016","journal-title":"Biotechniques"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1038\/onc.2017.205","article-title":"Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma","volume":"36","author":"Arslan","year":"2017","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., and Eccles, S.A. (2012). Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol., 10.","DOI":"10.1186\/1741-7007-10-29"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.biotechadv.2014.07.009","article-title":"Three-dimensional in vitro tumor models for cancer research and drug evaluation","volume":"32","author":"Xu","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/path.4366","article-title":"Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma","volume":"234","author":"Campos","year":"2014","journal-title":"J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/neuonc\/now045","article-title":"Large-scale assessment of the gliomasphere model system","volume":"18","author":"Laks","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1091\/mbc.E18-02-0123","article-title":"Mechanisms of invasion and motility of high-grade gliomas in the brain","volume":"29","author":"Mair","year":"2018","journal-title":"Mol. Biol. Cell"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Juarez-Mercado, K.E., Prieto-Martinez, F.D., Sanchez-Cruz, N., Pena-Castillo, A., Prada-Gracia, D., and Medina-Franco, J.L. (2020). Expanding the Structural Diversity of DNA Methyltransferase Inhibitors. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010017"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1073\/pnas.1221478110","article-title":"Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3","volume":"110","author":"Mao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/neuonc\/nov031","article-title":"Toward precision medicine in glioblastoma: The promise and the challenges","volume":"17","author":"Prados","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/neuonc\/nox044","article-title":"Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma","volume":"19","author":"McNeill","year":"2017","journal-title":"Neuro Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chembiol.2014.01.011","article-title":"MAP Kinase-Interacting Kinases-Emerging Targets against Cancer","volume":"21","author":"Diab","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1073\/pnas.1008136107","article-title":"Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development","volume":"107","author":"Ueda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.1005320107","article-title":"eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression","volume":"107","author":"Furic","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:22:08Z","timestamp":1782966128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":46,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132086"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132086","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}